New drug combo aims to recharge immune system against tough liver cancer
NCT ID NCT07157306
Summary
This study is testing whether adding a drug called gecacitinib to two other cancer drugs (donafenib and a PD-1 inhibitor) can help control advanced liver cancer that has started growing again after initial immunotherapy. It will enroll 35 adults to see if this combination is safe and can shrink tumors or slow their growth. The main goal is to see how many patients' tumors respond to this new treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.